Current OAG News
OAG Elects New President
TORONTO, ON – [November 28, 2017] The Ontario Association of Gastroenterology (OAG) elected Dr. Imran Rasul as President for the 2017-2019 year at its recent Annual General Meeting in Ottawa.
We are pleased to announce the recipient of the OAG/CAG Resident Research Award given in celebration of the OAG’s 20th anniversary
Dr. Katherine Prowse completed her medical training at MUA after a four year B.Sc. in Chemistry at Dalhousie University. At Northeast Ohio Medical University/Akron Children's Hospital, she completed her core Paediatric residency program and Paediatric Gastroenterology fellowship at McMaster University. She is currently in her final year of the Clinical Investigator Program at McMaster University. She is conducting research on the Influence of Antidepressants in Pregnancy on the Microbiome of the Offspring. She is also pursuing her Masters of Medical Science focusing on the microbiome, predictive genomics and metabolomics exploring their involvement in intestinal inflammation under the supervision of Dr. Elyanne Ratcliffe.
IBD Consensus Document
Ontario Association of Gastroenterologists Consensus Statement on the Ontario Reimbursement Criteria for Biologic Therapies in Inflammatory Bowel Disease
The Ontario Association of Gastroenterologists (OAG) and the Ontario Public Drug Plan (OPDP) have a common goal of providing excellence in health care to patients living with inflammatory bowel disease (IBD). With this in mind, the OAG formed a consensus group to review the current Exceptional Access Program (EAP) reimbursement criteria (updated August 1, 2015) for the use of biologic therapies in IBD in Ontario. Taking into consideration recent treatment guidelines and the most robust clinical data for all available therapies, this group developed several recommendations that will further align the EAP criteria with current evidence.
Ontario Association of Gastroenterology Consensus Group:
Statement on the Introduction of Subsequent Entry Biologics in Canada
The introduction of subsequent entry biologic (SEB) therapies provides an important opportunity to increase treatment options for both patients and providers and to improve the collective affordability of biologic agents. However, the complex structures of SEBs make generation of biologically identical molecules a challenge (Devlin et al., 2013), and even subtle differences between SEBs and innovators may translate into clinically relevant variations in efficacy, safety, and immunogenicity. Such variations are of significant concern to the Ontario Association of Gastroenterologists (OAG) and several other groups (eg, the Canadian Association of Gastroenterologists [CAG]) (Devlin et al., 2013; Endrenyi et al., 2014), as patients with inflammatory bowel disease (IBD) represent a very sick and vulnerable patient population.
OAG's Response to Task Force Recommendations on Colon Cancer Screening
TORONTO, ON – (February 29, 2016) - The Ontario Association of Gastroenterology (OAG) believes that “Colonoscopy is probably the best colon cancer screening test, it's just not proven yet,” according to OAG President Dr. Iain Murray. “The OAG is concerned that a recent report is being understood as saying ‘don’t do colonoscopies’, and that’s an incorrect understanding,” Murray states. He adds that colonoscopies promote prevention of cancer, thus supporting the current emphasis in health care on overall wellness, and not just treatment.